Wednesday, July 31, 2019

Novartis’ Kisqali extends survival in second late-stage breast cancer study

›
Results  from a second Phase 3 clinical,  MONALEESA-3 , evaluating Novartis’ ( NVS   +0.6% ) CDK4/6 inhibitor Kisqali (ribociclib), combine...

Eloxx Pharma on go with mid-stage study of ELX-02 in CF; shares ahead 6%

›
Thinly traded micro cap Eloxx Pharmaceuticals ( ELOX   +5.6% )  announces  that the FDA has signed off on its IND for a Phase 2 clinical tr...

STAAR Surgical EPS beats by $0.04, beats on revenue

›
STAAR Surgical (NASDAQ: STAA ): Q2 Non-GAAP EPS of $0.14  beats by $0.04 ; GAAP EPS of $0.08  beats by $0.04 . Revenue of $39.66M (+17.0%...

Vanda Pharmaceuticals EPS beats by $0.26, beats on revenue

›
Vanda Pharmaceuticals (NASDAQ: VNDA ): Q2 Non-GAAP EPS of $0.28  beats by $0.26 ; GAAP EPS of $0.21  beats by $0.19 . Revenue of $59.06M ...

MacroGenics EPS beats by $0.37, misses on revenue

›
MacroGenics (NASDAQ: MGNX ): Q2 GAAP EPS of -$0.65  beats by $0.37 . Revenue of $10.59M (-43.8% Y/Y)  misses by $0.83M . Press Release ...

Vertex Pharma up 2% after hours on Q2 beat, guidance raise

›
Vertex Pharmaceuticals (NASDAQ: VRTX )  Q2 results  ($M): Revenues: 941.3 (+25.1%); product sales: 940.4 (+25.4%). Key product sales: Sym...

ACADIA Pharma EPS beats by $0.08, beats on revenue

›
ACADIA Pharma (NASDAQ: ACAD ): Q2 GAAP EPS of -$0.38  beats by $0.08 . Revenue of $83.21M (+45.8% Y/Y)  beats by $10.71M . Shares  +1.7...